Objective: The primary objective of this study is to improve the solubility and dissolution rate of diacerein, a poorly soluble BCS Class II drug, by developing inclusion complexes with Hydroxy Propyl β-Cyclodextrin (HPβCD) and solid dispersions using PEG 6000 Method: A strategic approach was taken to develop solid dispersions of diacerein using three distinct techniques: kneading, melting, and physical mixing, with varying ratios of HPβCD and PEG 6000. By carefully selecting the optimal polymer and drug-to-polymer ratio, we successfully enhanced diacerein's physical stability, solubility, and dissolution rate, which paves the way for improved therapeutic outcomes Results and Discussion: Our optimized HPβCD-based solid dispersion achieved a remarkable six-fold (1.909±0.34 mg/ml) increase in diacerein solubility, a significant leap forward in enhancing the drug's therapeutic potential. Advanced characterization studies using FTIR, PXRD, and DSC revealed a successful transformation from crystalline to amorphous form, which unlocks the key to enhanced solubility and dissolution rate. This approach has the potential to revolutionize the delivery of poorly soluble drugs like diacerein Conclusion: Our research reveals that the kneading method, combined with a 1:1 ratio of diacerein to HPβCD, unlocks unprecedented solubility levels, setting the stage for a major breakthrough in treating patients with poorly soluble drugs. This strategy holds immense promise for enhancing therapeutic effectiveness, offering new hope for improved patient outcomes.
Soni et al. (Mon,) studied this question.